AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

2020 Medical Devices Pipeline Assessment for Immunohematology Tests - Featuring Grifols, Alba Bioscience & Amity University Among Others - ResearchAndMarkets.com

December 21, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Dec 21, 2020--

The “Immunohematology Tests - Medical Devices Pipeline Assessment, 2020” report has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive information about the Immunohematology Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

ADVERTISEMENT

Immunohematology Tests includes studies of antigen-antibody reactions and analogous phenomena as they relate to the pathogenesis and clinical manifestations of blood disorders. This category includes blood typing reagents and antibody detection reagents.

Companies Mentioned

  • AbSorber AB
  • Alba Bioscience Limited
  • Amity University
  • Biofortuna Ltd
  • Calviri Inc
  • Grifols SA
  • Ortho-Clinical Diagnostics Inc
  • Quotient Ltd
  • SiDx Inc

Scope

  • Extensive coverage of the Immunohematology Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Immunohematology Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry

Reasons to Buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Immunohematology Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

ADVERTISEMENT

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Immunohematology Tests Overview

3 Products under Development

3.1 Immunohematology Tests - Pipeline Products by Stage of Development

3.2 Immunohematology Tests - Pipeline Products by Segment

3.3 Immunohematology Tests - Pipeline Products by Territory

3.4 Immunohematology Tests - Pipeline Products by Regulatory Path

3.5 Immunohematology Tests - Pipeline Products by Estimated Approval Date

4 Immunohematology Tests - Pipeline Products under Development by Companies

4.1 Immunohematology Tests Companies - Pipeline Products by Stage of Development

4.2 Immunohematology Tests - Pipeline Products by Stage of Development

5 Immunohematology Tests Companies and Product Overview

6 Immunohematology Tests - Recent Developments

7 Appendix

7.1 Methodology

7.2 About the Publisher

7.3 Contact

7.4 Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/ojqml3

View source version on businesswire.com:https://www.businesswire.com/news/home/20201221005409/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: MEDICAL DEVICES HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 12/21/2020 08:10 AM/DISC: 12/21/2020 08:10 AM

http://www.businesswire.com/news/home/20201221005409/en